Insight CSB
Comprehensive genomic profiling of solid tumours from a blood sample
Liquid biopsy cancer genetic test
A high-precision multi-biomarker test using blood samples to extract circulating tumour DNA (ctDNA) to detect somatic variants across 523 genes with high sensitiviy and specificity.
Our most comprehensive blood-based tumour genomic test.
What it is:
The CSB test analyses a broad range of cancer-related genes from a blood sample to provide a detailed understanding of your tumour biology – with results written for people, not just specialists.
What it is for:
Designed for people who want the fullest possible insight, particularly when:
- Standard of care treatments are know not to be very effective for you particular cancer
- Standard treatment options have been exhausted
- You want to explore what else might exist beyond routine care
- You want a report you can actually use in conversations about next steps
What it includes:
- Single Nucleotide Variants (SNVs) & Insertion-Deletions (Indels) (523 genes)
- Copy Number Variations (CNVs) (59 genes)
- Fusions (23 genes)
- HLA Genes (3)
- Histone Genes (16)
- Tumour Mutation Burden (TMB)
- Microsatellite Instability (MSI)
- Tumour Fraction (TFx) estimate
Why it is different:
- Broader gene coverage than other leading market tests
- UK-relevant treatment and clinical trial options, explained in context
- A clear, human-readable summary – not just technical findings
Price: £3,250
The CSB panel analyses 523 genes for SNVs/InDels, 59 genes for CNVs, and 23 genes for fusions. Note: Some genes are analyzed for multiple alteration types (e.g., FGFR1 is analyzed for SNVs, CNVs, and Fusions).
● SNVs & InDels Panel (523):
ABL1, ABL2, ACVR1, ACVR1B, AKT1, AKT2, AKT3, ALK, ALOX12B, ANKRD11, ANKRD26, APC, AR, ARAF, ARFRP1, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXIN2, AXL, B2M, BAP1, BARD1, BBC3, BCL10, BCL2, BCL2L1, BCL2L11, BCL2L2, BCL6, BCOR, BCORL1, BCR, BIRC3, BLM, BMPR1A, BRAF, BRCA1, BRCA2, BRD4, BRIP1, BTG1, BTK, C11orf30, CALR, CARD11, CASP8, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD276, CD74, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CENPA, CHD2, CHD4, CHEK1, CHEK2, CIC, CREBBP, CRKL, CRLF2, CSF1R, CSF3R, CSNK1A1, CTCF, CTLA4, CTNNA1, CTNNB1, CUL3, CUX1, CXCR4, CYLD, DAXX, DCUN1D1, DDR2, DDX41, DHX15, DICER1, DIS3, DNAJB1, DNMT1, DNMT3A, DNMT3B, DOT1L, E2F3, EED, EGFL7, EGFR, EIF1AX, EIF4A2, EIF4E, EML4, EP300, EPCAM, EPHA3, EPHA5, EPHA7, EPHB1, ERBB2, ERBB3, ERBB4, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERG, ERRFI1, ESR1, ETS1, ETV1, ETV4, ETV5, ETV6, EWSR1, EZH2, FAM123B, FAM175A, FAM46C, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FAS, FAT1, FBXW7, FGF1, FGF10, FGF14, FGF19, FGF2, FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, FH, FLCN, FLI1, FLT1, FLT3, FLT4, FOXA1, FOXL2, FOXO1, FOXP1, FRS2, FUBP1, FYN, GABRA6, GATA1, GATA2, GATA3, GATA4, GATA6, GEN1, GID4, GLI1, GNA11, GNA13, GNAQ, GNAS, GPR124, GPS2, GREM1, GRIN2A, GRM3, GSK3B, H3F3A, H3F3B, H3F3C, HGF, HIST1H1C, HIST1H2BD, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I, HIST1H3J, HIST2H3A, HIST2H3C, HIST2H3D, HIST3H3, HLAA, HLAB, HLAC, HNF1A, HNRNPK, HOXB13, HRAS, HSD3B1, HSP90AA1, ICOSLG, ID3, IDH1, IDH2, IFNGR1, IGF1, IGF1R, IGF2, IKBKE, IKZF1, IL10, IL7R, INHA, INHBA, INPP4A, INPP4B, INSR, IRF2, IRF4, IRS1, IRS2, JAK1, JAK2, JAK3, JUN, KAT6A, KDM5A, KDM5C, KDM6A, KDR, KEAP1, KEL, KIF5B, KIT, KLF4, KLHL6, KMT2B, KMT2C, KMT2D, KRAS, LAMP1, LATS1, LATS2, LMO1, LRP1B, LYN, LZTR1, MAGI2, MALT1, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAP3K13, MAP3K14, MAP3K4, MAPK1, MAPK3, MAX, MCL1, MDC1, MDM2, MDM4, MED12, MEF2B, MEN1, MET, MGA, MITF, MLH1, MLL, MLLT3, MPL, MRE11A, MSH2, MSH3, MSH6, MST1, MST1R, MTOR, MUTYH, MYB, MYC, MYCL, MYCN, MYD88, MYOD1, NAB2, NBN, NCOA3, NCOR1, NEGR1, NF1, NF2, NFE2L2, NFKBIA, NKX21, NKX31, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NPM1, NRAS, NRG1, NSD1, NTRK1, NTRK2, NTRK3, NUP93, NUTM1, PAK1, PAK3, PAK7, PALB2, PARK2, PARP1, PAX3, PAX5, PAX7, PAX8, PBRM1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PDK1, PDPK1, PGR, PHF6, PHOX2B, PIK3C2B, PIK3C2G, PIK3C3, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIM1, PLCG2, PLK2, PMAIP1, PMS1, PMS2, PNRC1, POLD1, POLE, PPARG, PPM1D, PPP2R1A, PPP2R2A, PPP6C, PRDM1, PREX2, PRKAR1A, PRKCI, PRKDC, PRSS8, PTCH1, PTEN, PTPN11, PTPRD, PTPRS, PTPRT, QKI, RAB35, RAC1, RAD21, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RAF1, RANBP2, RARA, RASA1, RB1, RBM10, RECQL4, REL, RET, RFWD2, RHEB, RHOA, RICTOR, RIT1, RNF43, ROS1, RPS6KA4, RPS6KB1, RPS6KB2, RPTOR, RUNX1, RUNX1T1, RYBP, SDHA, SDHAF2, SDHB, SDHC, SDHD, SETBP1, SETD2, SF3B1, SH2B3, SH2D1A, SHQ1, SLIT2, SLX4, SMAD2, SMAD3, SMAD4, SMARCA4, SMARCB1, SMARCD1, SMC1A, SMC3, SMO, SNCAIP, SOCS1, SOX10, SOX17, SOX2, SOX9, SPEN, SPOP, SPTA1, SRC, SRSF2, STAG1, STAG2, STAT3, STAT4, STAT5A, STAT5B, STK11, STK40, SUFU, SUZ12, SYK, TAF1, TBX3, TCEB1, TCF3, TCF7L2, TERC, TERT, TET1, TET2, TFE3, TFRC, TGFBR1, TGFBR2, TMEM127, TMPRSS2, TNFAIP3, TNFRSF14, TOP1, TOP2A, TP53, TP63, TRAF2, TRAF7, TSC1, TSC2, TSHR, U2AF1, VEGFA, VHL, VTCN1, WISP3, WT1, XIAP, XPO1, XRCC2, YAP1, YES1, ZBTB2, ZBTB7A, ZFHX3, ZNF217, ZNF703, ZRSR2
● CNVs (59):
AKT2, ALK, AR, ATM, BRAF, BRCA1, BRCA2, CCND1, CCND3, CCNE1, CDK4, CDK6, CHEK1, CHEK2, EGFR, ERBB2, ERBB3, ERCC1, ERCC2, ESR1, FGF1, FGF10, FGF14, FGF19, FGF2, FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, JAK2, KIT, KRAS, LAMP1, MDM2, MDM4, MET, MYC, MYCL, MYCN, NRAS, NRG1, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PTEN, RAF1, RET, RICTOR, RPS6KB1, TFRC
● HLA Genes (3):
HLAA, HLAB, HLAC
● Histone Genes (16):
HIST1H1C, HIST1H2BD, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I, HIST1H3J, HIST2H3A, HIST2H3C, HIST2H3D, HIST3H3
● Fusion Genes (23):
ABL1, ALK, BCR, BRAF, CD74, EGFR, ETV1, ETV4, ETV6, EWSR1, FGFR2, FGFR3, NAB2, NTRK1, NTRK2, NUTM1, PAX3, PAX8, PPARG, RET, ROS1, TFE3, TMPRSS2
Ready to book an Insight CSB test?
Want to speak to one of our team?
About the clinically validated cancer biomarkers in the Insight CSB genetic test
Circulating Tumour DNA (ctDNA)
The extraction of ctDNA from a simple blood sample is recognised by international clinical guidelines, including ESMO’s recommendations for advanced cancer, as a valid method to identify actionable mutations and direct targeted therapies without the need for invasive surgery.
Tumour Mutational Burden (TMB)
Tumour Mutation Burden (TMB) measures the total number of mutations present in your cancer cells. Massive pan-tumour studies have shown that a high mutational burden is extensively linked to improved responses to modern immunotherapies across a wide range of solid tumours.
Microsatellite Instability (MSI)
Microsatellite Instability (MSI) is a critical feature of how DNA repairs itself. Peer-reviewed research establishes MSI as a predictive biomarker for cancer immunotherapy, helping oncologists understand if your immune system can be effectively stimulated to attack the tumour.
Tumour Fraction (TFx) Estimates
Your report includes a Tumour Fraction estimate, which calculates the proportion of the cell-free DNA isolated in your blood sample that is tumour DNA. Accurately measuring this is emerging as a powerful non-invasive biomarker to assess overall tumour burden and monitor disease progression.
Want to learn more about ctDNA testing?
Demystifying cancer genomics: In this short video series, Medical Oncologist Dr. Christoph Oing explains how analysing ctDNA from a simple blood sample may reveal personalised, targeted treatment options for your cancer.
To find out if this or any of our genomic tests are right for you, please book a free discovery call below
Understanding RareCan's Blood-Based Cancer Genomic Tests in more detail
What is this test?
Insight CSB is a genomic (DNA-based) test designed to look for genetic changes in cancer using a simple blood sample. Tumours can release tiny fragments of DNA into the bloodstream. This is called circulating tumour DNA (ctDNA).
By analysing ctDNA, this test can provide information about the genetic features of a cancer without needing a tissue biopsy, or alongside one if tissue testing has already been done.
What does the test look for?
The test examines:
- Small DNA changes (mutations) across 523 genes
- Extra or missing copies of genes in 59 genes
- Gene fusions involving 23 genes
- Certain immune-related genes (HLA-A, HLA-B, HLA-C)
- Microsatellite instability (MSI), a feature of how DNA repair works
- Tumour mutational burden (TMB), a measure of how many mutations are present
These features may help doctors understand:
- how a cancer behaves,
- whether certain treatments or clinical trials might be relevant,
- how a tumour’s genetics change over time.
How is the test done?
- A blood sample is taken in a clinic or at home.
- The sample is sent to a genetics laboratory.
- DNA fragments in the blood are analysed using advanced sequencing technology.
- A report is produced and shared with you and your healthcare professional.
What can the results tell me?
The test may:
- identify genetic changes linked to your cancer,
- show that no reportable changes were detected,
- identify changes whose significance is not yet fully understood,
- occasionally be unable to produce a result due to technical reasons.
Your doctor will explain what the results mean in the context of your overall medical care.
Important limitations to understand
- Not all cancers release enough DNA into the blood. A normal result does not rule out cancer or genetic changes.
- The teb can come from normal blood cells rather than the tumour.
- The test cannot on its own decide treatment and should not replace medical advice or other tests.
Will this test tell me which treatment I will get?
Not necessarily. While the test may highlight genetic features linked to certain treatments or trials, it does not guarantee:
- access to a specific medicine,
- NHS availability,
- insurance approval,
- or that a treatment will work.
Who should I talk to about my results?
Always discuss your results with your doctor or specialist, who can explain what they mean for you and what steps, if any, should be taken next.
Other Genetic Tests
RareCan offers more than one type of genomic test. To see what else is available, click on the button below.
About our tests
- Our liquid biopsy tests work by analysing cell-free DNA (cfDNA) circulating in your blood to identify and characterise tumour-derived fragments (circulating tumour DNA, or ctDNA).
- Our tissue-based tests work by analysing tumour DNA from samples stored by your hospital following biopsy or surgery.
- The tests use Next Generation Sequencing (NGS) on high throughput Illumina platforms to provide a genomic profile of your cancer.
- Our tests are extensively validated, accredited by the American College of Pathologists (CAP) and performed in an ISO 15198 accredited laboratory.
- Analysis and reporting is undertaken as per international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified mutation database for variant interpretation and reporting.
- The output from the test is a report highlighting genetic variants found, providing information for clinicians on the potential relevance of any variants, and listing out clinical trials that might be treatment options based on the genomic profile of your cancer.
Regulatory information / disclaimer
- RareCan Insight genomic tests are registered with the Medicines and Healthcare products Regulatory Agency (MHRA) as Class 1 in vitro diagnostic medical devices.
- They are intended for use by healthcare professionals for the qualitative identification of specific somatic variants in circulating tumour DNA (ctDNA) extracted from human whole blood or tumour DNA (tDNA) extracted from tumour tissue samples.
- The tests are intended to support clinicians in identifying potential clinical trials for which you may be eligible.
- The sample collection kits are intended for use by qualified phlebotomists and are not intended for patient self-testing or self-sampling.
- Results must be interpreted by a qualified healthcare professional in conjunction with your full clinical history, other diagnostic test results, and relevant clinical guidelines.
- The results are not intended to be used as the sole basis for treatment decisions, and further confirmatory testing may be required.
